Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Digital Scanner Optimized for Visible and Fluorescence Microscopy Applications

By LabMedica International staff writers
Posted on 05 May 2015
A new microscope scanner accessory designed to simplify digital pathology studies was introduced at a recent cancer research conference.

Leica Biosystems (Nussloch, Germany) introduced the Aperio VERSA, a combination digital pathology research scanner for brightfield, fluorescence, and FISH (fluorescence in situ hybridization) imaging, at the April 2015 American Association for Cancer Research annual meeting in Philadelphia (PA, USA). More...


The manufacturer described the Aperio VERSA, which is based on the Leica DM600 B microscope, as combining an unsurpassed optical path with precision stage registration, ensuring accurate, high resolution images for the most sophisticated multiplexing studies. Automatic switching between dedicated brightfield and fluorescent cameras ensures consistent, crisp images. The wide range of objective lenses from 1.25x to 63x, with motorized nose piece for automatic changing, enables users to readily scan slides at their ideal resolution. Furthermore, the automated oiler and oil-immersion lenses for 40x and 63x facilitates capture of the high resolution scans in batch and unattended modes.

Once scanned, the Aperio VERSA images are integrated into a comprehensive range of image analysis solutions. The system can be optimized for local, workstation-based, single user analysis, or enterprise-level, multi-user quantification. With a broad portfolio for the detection and quantification of cellular, subcellular and molecular markers in both brightfield and fluorescence, algorithms are easily tuned, so they can be tailored for specific research requirements.

“The Aperio VERSA is a breakthrough for researchers searching for an affordable solution for their diverse imaging needs,” said Puneet Sarin, vice president and general manager of Leica Biosystems’ pathology imaging business. “This combined introduction of solutions, from advanced staining, to imaging and computerized image analysis, demonstrates our commitment to provide cutting-edge technology to drive new breakthroughs in biomarker discovery. We see the Aperio VERSA and research software as valuable tools for core laboratories, bringing increased efficiency and quality to research.”

Related Links:
Leica Biosystems



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.